Glycosidase inhibitors

1. A method for treating a condition selected from the group of tauopathy, Parkinson's disease and amyotrophic lateral sclerosis, said method comprising administering an effective amount of at least one compound of formula (I)

wherein

R 1 denotes Y, COA, COOA, COO—(CH 2 ) n —Ar or COO—(CH 2 ) n -Cyc;

R 2 , R 3 denote independently from one another Y or SO 2 Y;

R 4 denotes Cl, Br, I, COOY, SO 2 Y, CN, CAr 3 , (CH 2 ) m —Ar,

R 5 denotes (CH 2 ) n —Ar, (CH 2 ) n -Cyc, (CH 2 ) n -Het, (CH 2 ) n —O—Ar, (CH 2 ) n —CY(OH)—Ar, (CH 2 ) n —CO—Ar or (CH 2 ) n —NY—Ar;

X denotes CH 2 , CO or CH(OH);

Y denotes H or A;

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced independently from one another by Hal or in which one CH 2 group can be replaced by a —CH═CH— group;

Cyc denotes cycloalkyl having 3-7 C atoms, in which 1-4 H atoms can be replaced independently from one another by Hal or which can be substituted by Ar;

Ar denotes an unsaturated or aromatic mono- or bicyclic carbocycle having 3-12 C atoms, which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n —OY, (CY 2 ) n —NYY, COOY, CONYY, NHCOY, SO 2 Y, CN and phenoxy;

Het denotes an unsaturated or aromatic mono-, bi- or tricyclic heterocycle having 1-12 C atoms and 1-4 N atoms, which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n —OY, (CY 2 ) n —NYY, COOY, CONYY, NHCOY, SO 2 Y, SO 2 Ar, CN and thiophenyl;

Hal denotes F, Cl, Br or I;

m denotes 1, 2 or 3; and

n denotes 0, 1, 2, 3, 4, 5 or 6;

or a physiologically acceptable salt thereof to a mammal in need of such treatment.

2. The method according to claim 1 , wherein the condition is selected from the group of Progressive supranuclear palsy (PSP), Frontotcmporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Corticobasal degeneration (CBP), Pick's disease (PiD), Niemann Pick Disease (type c), Parkinson-dementia complex of Guam and Alzheimer's disease.

3. The method according to claim 1 , wherein

R 1 , R 2 , R 3 denote independently from one another H or A.

4. The method according to claim 3 , wherein

R 1 , R 2 , R 3 denote H.

5. The method according to claim 1 , wherein

R 5 denotes (CH 2 ) n —Ar, (CH 2 ) n -Cyc, (CH 2 ) n -Het, (CH 2 ) n —O—Ar or CY(OH)—Ar.

6. The method according to claim 1 , administering sub-formula (IA), (IB) or (IC)

wherein

R 6 denotes Cl, Br, I, COOY, CAr 3 or

R 7 denotes (CH 2 ) m —Ar or

R 8 denotes (CH 2 ) m —Ar; and

R 1 , R 2 , R 3 , R 5 , Y, Ar, Het, m and n have the meaning as defined in claim 1 ;

or a physiologically acceptable salt thereof.

7. The method according to claim 6 , administering sub-formula (IA-1) or (IA-2)

wherein

Hal denotes Cl, Br or I; and

R 5 and Y have the meaning as defined in claim 6 ;

or a physiologically acceptable salt thereof.

8. The method according to claim 1 , wherein

A denotes unbranched or branched alkyl having 1-6 C atoms,

in which 1-4 H atoms can be replaced independently from one another by Hal;

Ar denotes an aromatic mono- or bicyclic carbocycle having 3-12 C atoms,

which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n —OY, (CY 2 ) n —NYY, SO 2 Y, CN and phenoxy;

Het denotes an unsaturated or aromatic mono-, bi- or tricyclic heterocycle having 2-12 C atoms and 1-3 N atoms,

which can be mono-, di- or trisubstituted by at least one substituent selected from the group of Hal, A, (CH 2 ) n —OY, (CY 2 ) n —NYY, SO 2 Y, SO 2 Ar, CN and thiophenyl; or

n denotes 0, 1, 2, 3 or 4.

9. The method according to claim 1 , wherein the compound is selected from the group consisting of:

or a physiologically acceptable salt thereof.